Research Articles | Page 75 | Aplastic Anemia and MDS International Foundation

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journalsort ascending Bone Marrow Disease
A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome. Apr 2012 Ann Hematol. aplastic anemia
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab Jan 2017 Ann Hematol paroxysmal nocturnal hemoglobinuria (PNH)
Asymptomatic cerebral bleeds in patients with aplastic anemia. Mar 2012 Ann Hematol aplastic anemia
Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT Sep 2016 Ann Hematol myelodysplastic syndromes (MDS)
Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia Aug 2017 Ann Hematol aplastic anemia
Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis Feb 2015 Ann Hematol aplastic anemia
Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine. Jun 2013 Ann Hematol myelodysplastic syndromes (MDS)
Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide May 2014 Ann Hematol myelodysplastic syndromes (MDS)
Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II Nov 2016 Ann Hematol paroxysmal nocturnal hemoglobinuria (PNH)
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol Aug 2016 Ann Hematol myelodysplastic syndromes (MDS)